{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:30:46Z","timestamp":1773333046669,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s12032-018-1084-9","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T13:38:41Z","timestamp":1517405921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-term survival with modern therapeutic agents against metastatic melanoma\u2014vemurafenib and ipilimumab in a daily life setting"],"prefix":"10.1007","volume":"35","author":[{"given":"B. M.","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Peveling-Oberhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Faidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"H\u00f6tker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Weyer-Elberich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2013","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidences and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374\u2013403.","journal-title":"Eur J Cancer"},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med. 2004;351:998\u20131012.","journal-title":"N Engl J Med"},{"issue":"12","key":"1084_CR3","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S1470-2045(03)01280-4","volume":"4","author":"TK Eigentler","year":"2003","unstructured":"Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol. 2003;4(12):748\u201359.","journal-title":"Lancet Oncol"},{"key":"1084_CR4","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers. 2015;1:15003.","journal-title":"Nat Rev Dis Primers"},{"issue":"9919","key":"1084_CR5","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","volume":"383","author":"AM Eggermont","year":"2011","unstructured":"Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet. 2011;383(9919):816\u201327.","journal-title":"Lancet"},{"issue":"11","key":"1084_CR6","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00105-012-2447-3","volume":"63","author":"BM Rudolph","year":"2012","unstructured":"Rudolph BM, Groffik A, Stanger C, Loquai C, Grabbe S. Systemic therapy for malignant melanoma. Hautarzt. 2012;63(11):885\u201398.","journal-title":"Hautarzt"},{"key":"1084_CR7","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507\u201316.","journal-title":"N Engl J Med"},{"key":"1084_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600\u00a0K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15:323\u201332.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1084_CR9","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/cncr.29586","volume":"121","author":"AM Menzies","year":"2015","unstructured":"Menzies AM, Wilmott JS, Drummond M, et al. Clinicopathologic Features Associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF of combined BRAF and MEK inhibitors. Cancer. 2015;121(21):3826\u201335.","journal-title":"Cancer"},{"key":"1084_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O`Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med"},{"key":"1084_CR11","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517\u201326.","journal-title":"N Engl J Med"},{"issue":"17","key":"1084_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","volume":"33","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889\u201394.","journal-title":"J Clin Oncol"},{"key":"1084_CR13","first-page":"449","volume":"63","author":"S Kelderman","year":"2014","unstructured":"Kelderman S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother. 2014;63:449\u201358.","journal-title":"Cancer Immunol Immunother"},{"issue":"24","key":"1084_CR14","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21(24):5453\u20139.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"1084_CR15","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1016\/j.ejca.2015.09.007","volume":"51","author":"S Diem","year":"2015","unstructured":"Diem S, Kasenda B, Martin-Liberal J, et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer. 2015;51(18):2785\u201391.","journal-title":"Eur J Cancer"},{"issue":"19","key":"1084_CR16","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-16-0249","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4\u00fe and CD8\u00fe T Cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(19):4848\u201358.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1084_CR17","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-15-2412","volume":"22","author":"A Martens","year":"2016","unstructured":"Martens A, Wistuba-Hamprecht K, Geukes Foppen M. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908\u201318.","journal-title":"Clin Cancer Res"},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/CJI.0b013e31828eed39","volume":"36","author":"S Wilgenhof","year":"2013","unstructured":"Wilgenhof S, Du Four S, Vandenbroucke F, et al. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. J Immunother. 2013;36:215\u201322.","journal-title":"J Immunother"},{"issue":"5","key":"1084_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/CMR.0b013e3283650741","volume":"23","author":"S Abusaif","year":"2013","unstructured":"Abusaif S, Jradi Z, Held L, et al. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma. Melanoma Res. 2013;23(5):396\u2013401.","journal-title":"Melanoma Res"},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1084_CR21","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/cam4.475","volume":"4","author":"GT Gibney","year":"2015","unstructured":"Gibney GT, Gauthier G, Ayas C. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting. Cancer Med. 2015;4(8):1205\u201313.","journal-title":"Cancer Med"},{"issue":"7","key":"1084_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1634\/theoncologist.2014-0012","volume":"20","author":"JJ Harding","year":"2015","unstructured":"Harding JJ, Catalanotti F, Munhoz RR. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist. 2015;20(7):789\u201397.","journal-title":"Oncologist"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/ol.2015.4069","volume":"11","author":"L Khoja","year":"2016","unstructured":"Khoja L, Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology letters. 2016;11:1581\u20135.","journal-title":"Oncology letters"},{"issue":"11","key":"1084_CR24","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1016\/j.ejca.2015.04.010","volume":"51","author":"I Puzanov","year":"2015","unstructured":"Puzanov I, Amaravadi RK, McArthur GA, et al. Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: patterns of disease progression and clinical management of limited progression. Eur J Cancer. 2015;51(11):1435\u201343.","journal-title":"Eur J Cancer"},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12967-015-0716-5","volume":"13","author":"L Zimmer","year":"2015","unstructured":"Zimmer L, Eigentler TK, Kiecker F, et al. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Transl Med. 2015;13:351.","journal-title":"Transl Med"},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00262-013-1418-6","volume":"62","author":"AM Giacomo Di","year":"2013","unstructured":"Di Giacomo AM, Calabro L, Danielli R, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10\u00a0mg\/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62:1021\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"1084_CR27","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/CMR.0000000000000034","volume":"24","author":"F Fennira","year":"2014","unstructured":"Fennira F, Page C, Schneider P, et al. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial. Melanoma Res. 2014;24:75\u201382.","journal-title":"Melanoma Res"},{"issue":"4","key":"1084_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Lancet Oncol. 2014;15(4):436\u201344.","journal-title":"Lancet Oncol"},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1093\/annonc\/mdu573","volume":"26","author":"S Uguel","year":"2015","unstructured":"Uguel S, Loquai C, Kahler K, et al. A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival. Ann Oncol. 2015;26:573\u201382.","journal-title":"Ann Oncol"},{"key":"1084_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/annonc\/mdt587","volume":"25","author":"B Schilling","year":"2015","unstructured":"Schilling B, Sondermann W, Zhao F, et al. Differential influence of vemurafenib and dabrafenib on patients\u2019 lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol. 2015;25:747\u201353.","journal-title":"Ann Oncol"},{"key":"1084_CR31","doi-asserted-by":"crossref","unstructured":"Simeone E, Gentilcore G, Romano A, Daponte A, Caraco C, Grimaldi AM, et al. Immunological and biological changes during ipilimumab (Ipi) treatment and their correlation with clinical response and survival. J Clin Oncol 2012;30:abstr 8573(suppl).","DOI":"10.1200\/jco.2012.30.15_suppl.8573"},{"issue":"2","key":"1084_CR32","first-page":"158","volume":"14","author":"C Gebhardt","year":"2016","unstructured":"Gebhardt C, Lichtenberger R, Utikal J. Biomarker value and pitfalls of serum S100B in the follow-up of high-risk melanoma patients. J Dtsch Dermatol Ges. 2016;14(2):158\u201364.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/cncr.24951","volume":"116","author":"GY Ku","year":"2010","unstructured":"Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer. 2010;116:1767\u201375.","journal-title":"Cancer"},{"issue":"15","key":"1084_CR34","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1200\/jco.2009.27.15_suppl.3020","volume":"27","author":"D Berman","year":"2009","unstructured":"Berman D, Wolchok JD, Weber J, Hamid O, O\u2019Day S, Chasalow S. Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol. 2009;27(15):3020.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1084_CR35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1093\/annonc\/mdt027","volume":"24","author":"J Delyon","year":"2013","unstructured":"Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697\u2013703.","journal-title":"Ann Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1084-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1084-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1084-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T16:03:23Z","timestamp":1603728203000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1084-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1084-9","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"2 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"BML received speaker honoraria from Roche, Novartis and BMS and travel expenses from BMS and Novartis. SG received honoraria for advisory boards, oral presentations and travel expenses from Roche, Novartis, MSD and BMS. CL received honoraria for advisory boards and oral presentations from Amgen, MSD, Roche, BMS, Novartis, Leo, Pierre Fabre; consultant for Roche-Posay, Roche, BMS and Biontech; travel expenses from Roche, Amgen, BMS, MSD and Novartis. APO, DF, AMH and VWE declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"24"}}